



**Mayo Clinic Gastrointestinal Cancers 2018**  
***Current and Emerging Strategies in Multidisciplinary Care:***  
***Translating Evidence into Best Practices***  
March 1-3, 2018

***Program Schedule***

**Thursday, March 1, 2018**

---

12:00 p.m. Registration and Refreshments

12:45 Welcome Announcements

**INTERACTIVE CASE PRESENTATIONS**

**Moderator:** Robert R. McWilliams, M.D.

1:00 **Advanced Non-Metastatic Pancreas Cancer: How to Maximize Chances of Successful Resection?**  
**Case Presenter:** Mark J. Truty, M.D., M.S.  
**Panel:** Michael L. Kendrick, M.D., Robert R. McWilliams, M.D., Ramesh K. Ramanathan, M.D., Terence T. Sio, M.D., M.S., Mark J. Truty, M.D., M.S.

1:55 **Early Stage Rectal Cancer**  
**Discussion 1: Do Shorter Total Neo-Adjuvant Courses Make More Sense?**  
**Case Presenter:** Nitin Mishra, M.D.  
**Panel:** David A. Etzioni, M.D., Chris L. Hallemeier, M.D., Joleen M. Hubbard, M.D., Pashtoon M. Kasi, M.D., Amit Merchea, M.D., Nitin Mishra, M.D.  
  
**Discussion 2: Is There a Role for Non-Operative Management?**  
**Case Presenter:** Chris L. Hallemeier, M.D.  
**Panel:** David A. Etzioni, M.D., Chris L. Hallemeier, M.D., Joleen M. Hubbard, M.D., Pashtoon M. Kasi, M.D., Amit Merchea, M.D., Nitin Mishra, M.D.

2:50 Break

3:10 **Early Stage Gastro-Esophageal Cancer: How to Optimize Neoadjuvant Therapy to Maximize Benefit?**  
**Case Presenter:** Harry H. Yoon, M.D.  
**Panel:** Daniel H. Ahn, D.O., Jonathan B. Ashman, M.D., Ph.D., Dennis Wigle, M.D., Ph.D., Harry H. Yoon, M.D.

4:05 **Locally Advanced Hepatocellular Carcinoma: Local vs. Systemic Therapy**  
**Case Presenter:** Mitesh J. Borad, M.D.  
**Panel:** Mitesh J. Borad, M.D., Amit Mahipal, M.B.B.S., Kabir Mody, M.D., Sadeer J. Alzubaidi, M.D., Ph.D., Beau Toskich, M.D.

5:00 **Closing Remarks**

5:05 Adjourn

7:00 a.m. Continental Breakfast

7:50 Announcements

**SESSION I: EMERGING TREATMENT STRATEGIES IN GASTRO-ESOPHAGEAL CANCER**

**Moderator:** Jonathan B. Ashman, M.D., Ph.D.

8:00 **Integrating PET Scans in the Decision-Making for GE Cancer Treatment**  
Michael C. Roarke, M.D.

8:20 **Immunotherapeutic Strategies in GE Cancer: Who is a Candidate?**  
Harry H. Yoon, M.D.

8:40 **Anti-Angiogenic Agents in GE Cancer: Where Do They Fit in the Therapeutic Landscape?**  
Daniel Ahn, D.O.

9:00 **Minimally Invasive Surgical Interventions in Early-Stage GE Cancer**  
Dennis Wigle, M.D., Ph.D.

9:20 Break

**SESSION II: EMERGING STRATEGIES TO OPTIMIZE OUTCOME IN METASTATIC COLORECTAL CANCER (mCRC)**

**Moderator:** Axel Grothey, M.D.

9:40 **From Anatomical location to CMS classification: Implications on Treatment Approach**  
Heinz-Josef Lenz, M.D., FACP

10:00 **The Emerging Role of “Liquid Biopsies” in the Treatment Landscape of mCRC**  
John Strickler, M.D.

10:20 **BRAF and RAS Mutations in mCRC : How I Treat?**  
Scott Kopetz, M.D., Ph.D., FACP

10:40 **Immunotherapeutic Strategies in CRC: Beyond MSI-high and Advanced Settings?**  
Frank A. Sinicrope, M.D.

11:00 **Predictors of Outcome with Regorafenib and TAS102**  
Pashtoon M. Kasi, M.D.

11:20 **Care for the Elderly with mCRC**  
Joleen M. Hubbard, M.D.

11:40 Lunch

**SESSION III: OPTIMIZING OUTCOME IN EARLY STAGE AND OLIGO-METASTATIC COLORECTAL CANCER**

**Moderator:** Nitin Mishra, M.D.

- 12:30 p.m.            **Radioembolization in Liver-only or Liver-dominant mCRC: Is there a Fit?**  
Steven R. Alberts, M.D.
- 12:50                **Liver Resection in mCRC: Who is an Optimal Candidate?**  
Chee-Chee H. Stucky, M.D.
- 1:10                 **Survivorship in the Long-term Care of Patients with CRC**  
David A. Etzioni, M.D.
- 1:30                 **Optimal Duration in the Adjuvant Treatment of CRC: Do We Have an IDEA?**  
Axel Grothey, M.D.
- 1:50                 **Debate: Role of HIPEC in the Management of CRC with Peritoneal only Disease**  
**HIPEC Rules!** – Nabil Wasif, M.D.  
**Time to Move Beyond HIPEC!** – Amit Merchea, M.D.  
**Panel Discussion** – Nabil Wasif, M.D. and Amit Merchea, M.D.
- 2:30                 Break

**SESSION IV: INTERPRETATION OF CLINICAL TRIALS AND LARGE DATABASES IN GI CANCERS**

**Moderator:** Qian Shi, Ph.D.

- 2:50                **Clinical Trial Conduct and Monitoring**  
Fang-Shu Ou, Ph.D.
- 3:10                **Working with Large Databases (ACCENT, ARCAD, and IDEA):  
The Past as Prologue**  
Qian Shi, Ph.D.
- 3:30                **Novel Agents in GI Malignancies Outside of Immunotherapy**  
Tony Reid, M.D., Ph.D.
- 3:50                **Closing Remarks**
- 4:00                Adjourn

## Saturday, March 3, 2018

---

7:00 a.m. Continental Breakfast

7:50 Announcements

### **SESSION V: EMERGING TREATMENT STRATEGIES IN PANCREAS CANCER**

**Moderator:** Ramesh K. Ramanathan, M.D.

8:00 **Optimizing Sequencing in the Treatment of Metastatic Pancreas Cancer**  
Wen Wee Ma, M.B.B.S.

8:20 **Emerging Strategies in the Treatment of Metastatic Pancreas Cancer**  
Ignacio Garrido-Laguna, M.D., Ph.D.

8:40 **Total Neoadjuvant Treatment for Resectable Pancreas Cancer: Is it Time?**  
Mark J. Truty, M.D., M.S.

9:00 **Minimally Invasive Surgical Interventions in Pancreas Cancer**  
Michael L. Kendrick, M.D.

9:20 Break

### **SESSION VI: EMERGING STRATEGIES TO OPTIMIZE OUTCOME IN HEPATOBILIARY CANCERS**

**Moderator:** Daniel Ahn, D.O.

9:40 **Tyrosine Kinase Inhibitors Galore: What is the Optimal Sequence?**  
Mitesh J. Borad, M.D.

10:00 **Immunotherapeutic Strategies in HCC: A Shifting Landscape**  
Anthony B. El-Khoueiry, M.D.

10:20 **The Expanding Role of Proton Therapy in Localized Hepatobiliary Cancers**  
Jonathan B. Ashman, M.D., Ph.D.

10:40 **When to Refer Your Patient with Hepatobiliary Cancer for Consideration of Transplant?**  
Adyr A. Moss, M.D.

11:00 **Genetic Diversity in Biliary Cancer**  
Milind Javle, M.D.

11:20 **Debate: Role of Adjuvant Therapy in Biliary Cancer**  
**Chemotherapy is the Standard** – Bassel F. El-Rayes, M.D.  
**Observation is the Standard** – Kabir Mody, M.D.  
**Panel Discussion** – Bassel F. El-Rayes, M.D. and Kabir Mody, M.D.

12:00 p.m. Lunch

**SESSION VII: NEUROENDOCRINE CANCER**

**Moderator:** Amit Mahipal, M.D.

12:50                    **Surgical (including Liver Transplant) Options in Metastatic NET to the Liver:  
Who is a Candidate?**  
Amit K. Mathur, M.D.

1:10                    **Systemic Therapies in NET**  
Thorvardur R. Halfdanarson, M.D.

1:30                    **Emerging Strategies in the Treatment Landscape of NET**  
Jonathan R. Strosberg, M.D.

**SPECIAL LECTURE**

**Moderator:** Tanios S. Bekaii-Saab, M.D.

1:50                    **Her2 as a Target in GI Malignancies**  
John H. Strickler, M.D.

2:05                    **Closing Remarks**

2:10                    Adjourn